Impact of PD1 Blockade Added to Neoadjuvant Chemoradiotherapy on Rectal Cancer Surgery: Post-Hoc Analysis of the Randomized POLARSTAR Trial
Background Colorectal cancer is the third most common cancer type globally, with the greatest disease burden in East Asia. In China, 47% of newly diagnosed colorectal cancers are rectal cancers, of which 70% are radiologically staged as locally advanced (stage II/III) at diagnosis. For decades, neoadjuvant chemoradiotherapy (CRT) combined with tota...